Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy?
Front Immunol
; 11: 1102, 2020.
Artículo
en Inglés
| MEDLINE | ID: covidwho-477856
ABSTRACT
With the sudden outbreak of COVID-19 patient worldwide and associated mortality, it is critical to come up with an effective treatment against SARS-CoV-2. Studies suggest that mortality due to COVID 19 is mainly attributed to the hyper inflammatory response leading to cytokine storm and ARDS in infected patients. Sphingosine-1-phosphate receptor 1 (S1PR1) analogs, AAL-R and RP-002, have earlier provided in-vivo protection from the pathophysiological response during H1N1 influenza infection and improved mortality. Recently, it was shown that the treatment with sphingosine-1-phosphate receptor 1 analog, CYM5442, resulted in the significant dampening of the immune response upon H1N1 challenge in mice and improved survival of H1N1 infected mice in combination with an antiviral drug, oseltamivir. Hence, here we suggest to investigate the possible utility of using S1P analogs to treat COVID-19.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Oxadiazoles
/
Neumonía Viral
/
Esfingosina
/
Lisofosfolípidos
/
Infecciones por Coronavirus
/
Síndrome de Liberación de Citoquinas
/
Receptores de Esfingosina-1-Fosfato
/
Indanos
Tipo de estudio:
Estudio pronóstico
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Front Immunol
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Fimmu.2020.01102
Similares
MEDLINE
...
LILACS
LIS